Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.

Cancer science - 1 Sept 2021

Izutsu Koji, Ando Kiyoshi, Nishikori Momoko, Shibayama Hirohiko, Teshima Takanori, Kuroda Junya, Kato Koji, Imaizumi Yoshitaka, Nosaka Kisato, Sakai Rika, Hojo Seiichiro, Nakanishi Tadashi, Rai Shinya

Abstract excerpt

Tazemetostat is a selective, reversible, small-molecule inhibitor of the histone methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open-label, phase II study, we assessed the efficacy and safety of tazemetostat in Japanese patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma harboring the EZH2 mutation. Tazemetostat (800 mg twice daily) was given orally (28-day...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Lymphoma, Follicular

Share to Lymphoma, Large B-Cell, Diffuse

Share to Morpholines

Share to Progression-Free Survival

Share to Pyridones

Source

Open in PubMed Open full text

Identifiers

PMID: 34159682
DOI: 10.1111/cas.15040
PMCID: PMC8409398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.PMID 34159682Read ↗

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity Read ↗

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.Semantic proximity Read ↗

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

[INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].Semantic proximity Read ↗

Treating lymphoma is now a bit EZ-er.Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.Semantic proximity Read ↗

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.Semantic proximity Read ↗

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.Semantic proximity Read ↗

EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.Semantic proximity Read ↗

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.